These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results - WAVE Life Sciences ( NASDAQ:WVE )
Wave Life Sciences Ltd ( NASDAQ:WVE ) reported worse-than-expected third-quarter financial results on Monday. WAVE Life Sciences reported quarterly losses of 32 cents per share which missed the analyst consensus estimate of losses of 30 cents per share.
Wave Life Sciences ( WVE ) Earnings Transcript
Image source: The Motley Fool.Monday, Nov. 10, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Wave Life Sciences ( WVE ) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.67% and -41.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of ...
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to ...
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to ...
CytomX Therapeutics ( CTMX ) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -125.00% and -53.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
Presentation will highlight preclinical data supporting the potential of WVE-007 ( INHBE GalNAc-siRNA ) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing ...
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025 - WAVE Life Sciences ( NASDAQ:WVE )
Presentation will highlight preclinical data supporting the potential of WVE-007 ( INHBE GalNAc-siRNA ) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025 - WAVE Life Sciences ( NASDAQ:WVE )
CAMBRIDGE, Mass., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( NASDAQ:WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
Wave Life Sciences ( WVE ) Soars 8.8%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 ( GalNAc-siRNA ) " - "Next steps." ...
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models. WVE-007 is generally safe and well tolerated to date ...
Strength Seen in Wave Life Sciences ( WVE ) : Can Its 11.4% Jump Turn into More Strength?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, ...
Peering Into WAVE Life Sciences's Recent Short Interest - WAVE Life Sciences ( NASDAQ:WVE )
WAVE Life Sciences's WVE short interest as a percent of float has risen 3.37% since its last report. According to exchange reported data, there are now 17.32 million shares sold short, which is 14.71% of all regular shares that are available for trading.
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? - WAVE Life Sciences ( NASDAQ:WVE )
WVE-006 produces AAT protein at disease-protective levels in all treated patients. The monthly dosing regimen is under study, with more data expected in Q1 2026. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) Wave Life Sciences Ltd.
Crude Oil Falls Over 2%; Campbell's Earnings Top Estimates - Bruker ( NASDAQ:BRKR ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 150 points on Wednesday. The Dow traded down 0.37% to 45,130.04 while the NASDAQ rose 0.90% to 21,471.90. The S&P 500 also rose, gaining, 0.31% to 6,435.43. Communication services shares jumped by 3.1% on ...
Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earnings - BT Brands ( NASDAQ:BTBD ) , Senmiao Technology ( NASDAQ:AIHS )
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.04% to 45,277.17 while the NASDAQ rose 0.66% to 21,420.84. The S&P 500 also rose, gaining, 0.37% to 6,439.91.
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 ( 11.9 µM total ...
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics ( NASDAQ:AKRO ) , Apartment Inv & Mgmt ( NYSE:AIV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Ritu Baral initiated coverage on Akero Therapeutics, Inc.
Wave ( WVE ) Q2 Revenue Drops 56%
Wave Life Sciences ( NASDAQ:WVE ) , a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 ...
Wave Life Sciences ( WVE ) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Accenture ( NYSE:ACN ) , Allarity Therapeutics ( NASDAQ:ALLR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Alarum Technologies Ltd.
Illumina ( ILMN ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
CAMBRIDGE, Mass., July 23, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
CRISPR Therapeutics ( CRSP ) Moves 9.6% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism ( INHBE ) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions - WAVE Life Sciences ( NASDAQ:WVE )
Presentation to highlight WVE-007 ( INHBE GalNAc-siRNA ) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism ( INHBE ) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 ( INHBE GalNAc-siRNA ) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation ...
Wave Life Sciences ( WVE ) Reports Q1 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.41% and 34.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Geron ( GERN ) Reports Q1 Loss, Lags Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 25% and 18.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics ( MYGN ) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Wave Life Sciences ( WVE ) to Report a Decline in Earnings: What to Look Out for
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst ...
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Wave Life Sciences ( WVE ) Stock Jumps 6.1%: Will It Continue to Soar?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - WAVE Life Sciences ( NASDAQ:WVE )
Wave Life's WVE-N531 met all Phase 2 goals, showing exon skipping, dystrophin restoration. The therapy showed a 28.6% muscle fibrosis reduction, a 50% CK decline, and decreased IL-6/MCP-1, supporting its potential for DMD treatment Feel unsure about the market's next move?
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 - WAVE Life Sciences ( NASDAQ:WVE )
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks. additional functional benefits observed in other outcome measures including ...
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Adma Biologics ( ADMA ) Surges 10.2%: Is This an Indication of Further Gains?
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025. enrollment complete in first single dose cohort ...
Seer, Inc. ( SEER ) Reports Q4 Loss, Tops Revenue Estimates
Seer (SEER) delivered earnings and revenue surprises of 15% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Foghorn Therapeutics Inc. ( FHTX ) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Infinity ( NYSE:INR ) , Insmed ( NASDAQ:INSM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Roger Song initiated coverage on Wave Life Sciences Ltd.
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
CAMBRIDGE, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
SpringWorks Therapeutics ( SWTX ) Reports Q4 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -44.44% and 2.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
